Psychiatry

A report shows only 24%, 56%, and 62% of patients meet the criteria PSIL-AT for depression according to low-bound, mid-range, and upper-bound estimates, respectively.

A new study suggests lower cognitive functioning may be a risk factor for natural cause mortality in people with schizophrenia.

A recent study saw prescription fills for stimulants, and antidepressants increased from 2019 to 2022 but decreased for opioids.

In an interview, lead investigator Lauren Moran, MD, shared how the results inform clinical practice on safe amphetamine dosing.

A new study highlights the need for caution when prescribing high-dose amphetamines (≥ 30 mg) due to their psychosis and mania risk.

A phase 3 trial found mirtazapine ineffective in reducing breathlessness in respiratory disease patients, urging caution with off-label antidepressant use.

In an interview with HCPLive, Wadden discussed the findings of a post-hoc analysis, supporting how semaglutide is not linked to an increased suicidal ideation risk.

A post-hoc analysis of the STEP trials found semaglutide for weight management doesn’t increase depression or suicidal thoughts in individuals without major mental disorders.

This month in review highlights MDMA-assisted therapy coverage, experiences with zuranolone a year after its approval, and early positive data on potential treatments.

A phase 2 trial met its primary endpoint, showing NBI-1117568, the first M4 selective agonist, is effective and safe at treating adult schizophrenia.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

A new study significantly demonstrated semaglutide, but not liraglutide, is associated with suicidal ideation.

A new study found unvaccinated people have a greater risk of depression or serious mental health illnesses compared to vaccinated people.

In this episode of Crisis Point, PTSD experts and a trial participant react to the FDA’s decision on MDMA-assisted therapy for PTSD.

Preliminary Phase 1b data demonstrated the favorable safety and tolerability profile of VLS-01 buccal film, with psychedelic effects resolved by 120 minutes.

Cristina Pearse, an MDMA-assisted therapy trial participant, expresses disappointment in the FDA’s decision not to approve MDMA-assisted therapy.

The US FDA has issued a CRL and requested an additional phase 3 trial for MDMA-assisted therapy in the management of PTSD.

A new study revealed an increased risk of psychiatric and autoimmune comorbidities after an alopecia areata diagnosis.

Geoffrey Grammer, MD closes this series highlighting the administration options of esketamine, its safety profile, and the importance of monitoring patients using this treatment.

Robert Zalewski-Zaragoza, MD expands on the option of esketamine for treatment resistant depression, highlighting the unique mechanism of action and application.

William Sauve, MD shares the growing landscape of treatments for treatment resistant depression (TRD) and their mechanism of action, such as brain stimulation through electroconvulsive therapy or medication such as esketamine.

Harman Deol, MD begins this series presenting an overview of treatment resistant depression (TRD), highlighting its prevalence along with its impact on patients and the healthcare system.

A study suggests TMR can boost PTSD treatment by enhancing memory consolidation during sleep, showing significant symptom reduction without affecting sleep quality.

PTSD experts explore unmet PTSD needs, the potential of psychedelic therapies, and key unanswered questions about MDMA-assisted therapy for PTSD.

A recent study found a high prevalence of head injuries among law enforcement officers may make them more prone to experiencing mental health issues.